33 related articles for article (PubMed ID: 14583495)
1. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.
Takagi M; Honmura T; Watanabe S; Yamaguchi R; Nogawa M; Nishimura I; Katoh F; Matsuda M; Hidaka H
Invest New Drugs; 2003 Nov; 21(4):387-99. PubMed ID: 14586206
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.
Chilamakuri R; Rouse DC; Agarwal S
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631350
[TBL] [Abstract][Full Text] [Related]
3. A Review of the Recent Developments of Molecular Hybrids Targeting Tubulin Polymerization.
Ebenezer O; Shapi M; Tuszynski JA
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409361
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation and molecular docking investigation of new sulphonamide derivatives bearing naphthalene moiety as potent tubulin polymerisation inhibitors.
Wang G; Fan M; Liu W; He M; Li Y; Peng Z
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1402-1410. PubMed ID: 34157927
[TBL] [Abstract][Full Text] [Related]
5. Constrained Peptides with Fine-Tuned Flexibility Inhibit NF-Y Transcription Factor Assembly.
Jeganathan S; Wendt M; Kiehstaller S; Brancaccio D; Kuepper A; Pospiech N; Carotenuto A; Novellino E; Hennig S; Grossmann TN
Angew Chem Int Ed Engl; 2019 Nov; 58(48):17351-17358. PubMed ID: 31539186
[TBL] [Abstract][Full Text] [Related]
6. Effects of Genetic Variants of Nuclear Receptor Y on the Risk of Type 2 Diabetes Mellitus.
Wang Y; Yang S; Guan Q; Chen J; Zhang X; Zhang Y; Yuan Y; Su Z
J Diabetes Res; 2019; 2019():4902301. PubMed ID: 31205951
[TBL] [Abstract][Full Text] [Related]
7. PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis.
Kumar S; Kim J
Biomed Res Int; 2015; 2015():705745. PubMed ID: 26557691
[TBL] [Abstract][Full Text] [Related]
8. Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide.
Bagheri F; Safarian S; Eslaminejad MB; Sheibani N
Mol Biol Rep; 2014 Nov; 41(11):7387-94. PubMed ID: 25086620
[TBL] [Abstract][Full Text] [Related]
9. Death inducing and cytoprotective autophagy in T-47D cells by two common antibacterial drugs: sulphathiazole and sulphacetamide.
Mohammadpour R; Safarian S; Sheibani N; Norouzi S; Razazan A
Cell Biol Int; 2013 Apr; 37(4):348-58. PubMed ID: 23450781
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?
Dolfini D; Mantovani R
Cell Death Differ; 2013 May; 20(5):676-85. PubMed ID: 23449390
[TBL] [Abstract][Full Text] [Related]
11. A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule.
Liu ZL; Tian W; Wang Y; Kuang S; Luo XM; Yu Q
Acta Pharmacol Sin; 2012 Feb; 33(2):261-70. PubMed ID: 22301862
[TBL] [Abstract][Full Text] [Related]
12. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
[TBL] [Abstract][Full Text] [Related]
13. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
Strebhardt K
Nat Rev Drug Discov; 2010 Aug; 9(8):643-60. PubMed ID: 20671765
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle kinases as therapeutic targets for cancer.
Lapenna S; Giordano A
Nat Rev Drug Discov; 2009 Jul; 8(7):547-66. PubMed ID: 19568282
[TBL] [Abstract][Full Text] [Related]
15. The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation.
DiMaio MA; Mikhailov A; Rieder CL; Von Hoff DD; Palazzo RE
Mol Cancer Ther; 2009 Mar; 8(3):592-601. PubMed ID: 19258425
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
El-Khoury V; Breuzard G; Fourré N; Dufer J
Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
[TBL] [Abstract][Full Text] [Related]
17. Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression.
Medina-Gundrum L; Cerna C; Gomez L; Izbicka E
Invest New Drugs; 2005 Jan; 23(1):3-9. PubMed ID: 15528975
[TBL] [Abstract][Full Text] [Related]
18. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y.
Tanaka H; Ohshima N; Ikenoya M; Komori K; Katoh F; Hidaka H
Cancer Res; 2003 Oct; 63(20):6942-7. PubMed ID: 14583495
[TBL] [Abstract][Full Text] [Related]
19. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
Shareef MM; Brown B; Shajahan S; Sathishkumar S; Arnold SM; Mohiuddin M; Ahmed MM; Spring PM
Mol Cancer Res; 2008 Jan; 6(1):89-98. PubMed ID: 18234965
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
